This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm
Annals of Hematology Open Access 01 September 2021
-
Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome
Leukemia Open Access 20 May 2020
-
Down syndrome associated childhood myeloid leukemia with yet unreported acquired chromosomal abnormalities and a new potential adverse marker: dup(1)(q25q44)
Molecular Cytogenetics Open Access 13 March 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hasle H, Clemmensen IH, Mikkelsen M . Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355: 165–169.
Hasle H . Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 2001; 2: 429–436.
Hitzler JK, Zipursky A . Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005; 5: 11–20.
Webb DK . Optimizing therapy for myeloid disorders of Down syndrome. Br J Haematol 2005; 131: 3–7.
Abildgaard L, Ellebæk E, Gustafsson G, Abrahamsson J, Hovi L, Jonmundsson G et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol 2006; 85: 275–280.
Rao A, Hills RK, Stiller C, Gibson BE, De Graaf SS, Hann IM et al. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 2006; 132: 576–583.
Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17: 277–282.
Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's cancer group Study 2891. J Clin Oncol 2003; 21: 3415–3422.
Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M . AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005; 19: 1355–1360.
Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley JD, Howells WB et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's cancer group studies 2861 and 2891. Blood 1998; 91: 608–615.
Yamaguchi Y, Fujii H, Kazama H, Iinuma K, Shinomiya N, Aoki T . Acute myeloblastic leukemia associated with trisomy 8 and translocation 8;21 in a child with Down syndrome. Cancer Genet Cytogenet 1997; 97: 32–34.
Sato A, Imaizumi M, Koizumi Y, Obara Y, Nakai H, Noro T et al. Acute myelogenous leukaemia with t(8;21) translocation of normal cell origin in mosaic Down's syndrome with isochromosome 21q. Br J Haematol 1997; 96: 614–616.
Kurkjian C, Patel S, Kamble R, Dunn ST, Kern W, Kharfan-Dabaja MA . Acute promyelocytic leukemia and constitutional trisomy 21. Cancer Genet Cytogenet 2006; 165: 176–179.
Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, O'Marcaigh A et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004; 103: 2480–2489.
Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH . Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 2005; 37: 613–619.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hasle, H., Abrahamsson, J., Arola, M. et al. Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia 22, 1428–1430 (2008). https://doi.org/10.1038/sj.leu.2405060
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2405060
This article is cited by
-
The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm
Annals of Hematology (2022)
-
Clinical and biological aspects of myeloid leukemia in Down syndrome
Leukemia (2021)
-
Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome
Leukemia (2020)
-
Down syndrome associated childhood myeloid leukemia with yet unreported acquired chromosomal abnormalities and a new potential adverse marker: dup(1)(q25q44)
Molecular Cytogenetics (2018)
-
Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update
Current Hematologic Malignancy Reports (2016)